337 results about "Immunologic adjuvant" patented technology

A cancer immunotherapy method and composition for treating cancer in a patient comprised of vaccinating a patient with a vaccine comprised of the patient's own malignancy and an immunologic adjuvant, removing primed peripheral blood T lymphocytes from the patient, stimulating the primed T lymphocytes to differentiate into effector lymphocytes in vitro, stimulating the effector T lymphocytes to proliferate in vitro, and infusing the effector T lymphocytes back into the patient.

The invention discloses rhodococcus ruber and application of same as an immunologic adjuvant in preparing vaccine. The rhodococcus ruber is also called rhodococcus ruber RDC-01, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO. 16640. The rhodococcus ruber disclosed by the invention has the function of increasing and regulating the body immunity andis capable of nonspecifically enhancing the activity of TB (Tuberculosis) lymphocyte, macrophagocyte and NK cells and inducing multiple cell factors such as interferon, and the rhodococcus ruber canbe used as the immunologic adjuvant after being inactivated so as to be added in an oil-adjuvant inactive vaccine, so that generation of an animal antibody induced by the vaccine can be obviously promoted; compared with single use of the oil-adjuvant inactive vaccine, a high-titre antibody can be generated, the use is safe, long-term and short-term toxic and side effects are not generated, and anapplication prospect in the field of preparation of vaccines for animals is good.

The invention relates to a polymer nano carrier preparation as well as a preparation method and an application thereof. The nano carrier preparation employs a nano carrier micelle of a three-layer structure to carry DNA (Deoxyribonucleic Acid) antigen, protein antigen, polypeptide antigen and immunologic adjuvant. The polymer nano carrier preparation is good in stability and immunogenicity, and can not only prompt ingestion of antigen presentation cells such as dendritic cells for the antigen, but also remarkably induce organisms to make specific immune response.

The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.

The present invention discloses an application of ginseng total saponin or monomer saponin Rb1 as vaccine immunologic adjuvant. The ginseng total saponin or monomer saponin Rb1 and aluminium hydroxide are mixed and used as vaccine immunologic adjuvant, and as compared with traditional aluminium hydroxide adjuvant said invention possesses the following advantages: (1) its side effect is less; (2) said vaccine can be stored under the condition of frozen low-temp. and it can prolong effective period of vaccine; (3) its method is simple and convenient, its quality is easy to be controlled; and (4) it can induce body to produce higher humoral immunity response.

The invention belongs to the field of biomedicine, and particularly relates to an aluminum hydroxide gel-polysaccharide composite immunologic adjuvant and a preparation method and application thereof. The invention aims to provide a new immunologic adjuvant with good performance. The technical scheme is to provide a composite immunologic adjuvant. The composite immunologic adjuvant mainly contains aluminum hydroxide gel and polysaccharide serving as bacteria source. The aluminum hydroxide gel-polysaccharide composite immunologic adjuvant provided by the invention has the advantages of strong immunocompetence, high clinical safety and the like, and is an excellent composite immunologic adjuvant aiming at various antigens. The hepatitis vaccine and tumor vaccine prepared by taking the aluminum hydroxide gel-polysaccharide composite provided by the invention as adjuvant has stronger immune effect and anti-cancer effect, and thus new selection is provided for the development and application of vaccine.

The invention provides an anti-aflatoxin general type monoclonal antibody hybridoma cell line and application thereof, belonging to the field of food safety immunodetection. The cell line 1G6 provided by the invention is collected in the China General Microbiological Culture Collection Center (CGMCC) with a collection number of CGMCC No.7210. After an aflatoxin complete antigen is uniformly mixed with equivalent Quick Antibody immunologic adjuvant TM, an obtained mixture is injected to immunize BALB/c mice through leg muscle. B1-KLH (fumonisin B1-Keyhole Limpet Hemocyanin) is adopted for the first time of immunization, M1-KLH (fumonisin M1-Keyhole Limpet Hemocyanin) is adopted for the second time of immunization, and an M1 complete antigen (without containing adjuvant) is adopted for the last time of impaction immunization. Splenocytes of immunized mice are fused with myeloma cells through a PEG (polyethylene glycol) method, and the hybridoma cell line 1G6 is obtained through indirect ELISA (Enzyme-Linked Immuno Sorbent Assay) and indirect competence ELISA screening and three times of subcloning. A monoclonal antibody secreted from the cell line has better affinity and detection sensitivity for aflatoxins B1, B2, G1, G2 and M1, and can be used for immunodetection of the total quantity of the aflatoxins in the food safety.

The invention belongs to the technical field of medicine and relates to a use of cyclic dinucleotide cGAMP and its derivatives as immunologic adjuvants. The study result shows that cGAMP and its derivatives can stimulate the innate immunity of the human body, are effective immunomodulators, can significantly improve the immune response and antibody titer, can stimulate expression of immature dendritic cell surface histocompatible complex MHCII antigens and an enhancement molecule CD80/CD86, can increase secretion of cytokines and chemokines (such as interleukin and interferon), and can activate and enhance dendritic cells and T cells. Therefore, cGAMP and its derivatives can be used as potential immunologic adjuvants and play an important role in preparation of vaccines.

The invention relates to a bots antibacterial peptide adjuvant with an immune adjuvant role and a preparation method thereof, and a vaccine formulation containing the antibacterial peptide adjuvant and use thereof in preparation of the vaccine formulation. The antibacterial peptide is a polypeptide component extracted and separated from fly maggots, the cellular immunity and humoral immune response of immunized mice can be facilitated, the organism is induced to generate balanced Th1 type and Th2 type immunoreactions simultaneously, and the adjuvant characteristics better than those of the known aluminum plastic adjuvant in the prior art are displayed. The bots antibacterial peptide adjuvant can be used as an immunologic adjuvant for a plurality of vaccines to play an ideal immune effect. The vaccine of taking the antibacterial peptide as the adjuvant is simple in preparation process, simple and convenient in method, easy to control quality, convenient to use, and good in safety, and can be frozen to store.

The invention discloses a polysaccharide/PEI nanogel with reduction responsiveness, and a preparation method of the polysaccharide/PEI nanogel. The preparation method comprises following steps: a gel is prepared from a polysaccharide and PEI via electrostatic interaction; and then a disulfide cross-linking agent is added for crosslinking, and the polysaccharide/PEI nanogel with reduction responsiveness is obtained. The polysaccharide/PEI nanogel processes following ingredients, by weight, 1 to 100 parts of the polysaccharide, 1 to 100 parts of PEI, and 10 to 2000 parts of the disulfide cross-linking agent. The polysaccharide/PEI nanogel possesses low toxicity; is capable of encapsulating genes or proteins preferably, and protecting substances encapsulated by the polysaccharide/PEI nanogel from degradation effect of lysozyme, and from cytophagy by immune cells; is capable of realizing response on reducing conditions in cells, and increasing release rate of the substances encapsulated by the polysaccharide/PEI nanogel; and can be used as a nanogel carrier to load proteins, polypeptides or nucleic acids. The polysaccharide/PEI nanogel also possesses effects of an immunologic adjuvant. All processes of the preparation method are performed in water, and no environmental pollution is caused.

The invention relates to a method for preparing a nano aluminum hydroxide gel adjuvant, belonging to the technical field of processes for preparing immunologic adjuvant of biological products for animals. The method comprises the following steps: mixing an aluminum salt solution and a soda solution which serve as raw materials, and adding a certain amount of stabilizing agent during mixing; shearing by a high-shearing emulsifying machine to obtain the nano aluminum hydroxide solution preliminarily; precipitating, washing and re-precipitating to obtain nano aluminum hydroxide gel; preparing a solution from the nano aluminum hydroxide; and compounding the solution with an inactivated bacterial solution to obtain an inactivated vaccine. The nano aluminum hydroxide gel adjuvant prepared by adopting the method is uniform in particle size distribution, has high purity, strong adsorbability and no side effect and has a good application prospect in the aspect of preparation of immunologic adjuvant.

The invention relates to a vaccine immunologic adjuvant and a vaccine, in particular to an astragalus polyose adjuvant and application thereof in an I-riemerella anatipestifer inactivated vaccine. The vaccine adjuvant is an astragalus polyose solution with the concentration of 30 milligrams per milliliter. An astragalus polyose inactivated vaccine for the I-riemerella anatipestifer is prepared from a riemerella anatipestifer RA-1 inactivated bacteria liquid as the vaccine and the astragalus polyose solution as the adjuvant through mixing. The astragalus polyose adjuvant improves the immune efficacy of the prior inactivated vaccine, effectively prevents and controls infectious serositis of duck, and provides a basis for the research of a novel immunologic adjuvant. The vaccine has good safety and immunogenicity, and can effectively prevent the infectious serositis of duck.

The invention provides a manganese dioxide nanometer material. The manganese dioxide nanometer material comprises manganese dioxide nanoparticles and carried matter, wherein the carried matter is compounded onto the surface of the manganese dioxide nanoparticle; the carried matter comprises oligonucleotide CpG and/or antigen; the antigen comprises protein antigen and/or polypeptide antigen. The provided manganese dioxide nanometer material has the advantages that the immunostimulation function of an immunologic adjuvant CpG is greatly improved, the immunity protection function of vaccine is improved, and the inherent defect of effective improving of immune reaction by a large amount of CpG because the oligonucleotide CpG is used as an immunologic stimulant and cannot easily enter the body lymph glands is solved; the manganese dioxide nanometer material is used as a vaccine adjuvant, and can carry the antigen, especially the protein antigen, so that the intake on the antigen by the immune cells in the lymph glands is effectively improved, and the immunogenicity of the antigen is improved; the nanometer adjuvant can be biologically degraded, and can be gradually degraded into manganese ions (Mn<2+>) under the weak acid environment, such as lysosome, and the manganese ions are finally discharged out of the human body.

The invention belongs to the technical field of medicine, relates to polysaccharide components extracted from isatis roots, and in particular relates to polysaccharide components S1, S3 and S4 extracted from isatis roots. The invention also relates to a preparation method of the polysaccharide components S1, S3 and S4, and use thereof as a vaccine adjuvant or an immunomodulator or for preparing a vaccine composition. The results of activity experiments indicate that the separated polysaccharide components S1, S3 and S4 provided by the invention have vaccine adjuvant activity and immunoregulation effec, thereby providing a new option for immunologic adjuvants.

The invention relates to a preparation method and application of fusion protein (chIL-2-HN fusion protein) of recombining poultry interleukin-2 (IL-2) and newcastle disease virus hemagglutinin-neuraminidase (HN), belonging to the technical field of biological engineering. The fusion protein is fused by poultry IL-2 protein and newcastle disease virus HN protein by flexible Linker peptide; a DNA sequence for coding the fusion protein is inserted into an expression vector pPICZ alpha A; saccharomycete X-33 is electrically converted to obtain a genetically engineered microorganism for efficiently expressing recombination chIL-2-HN fusion protein which is prepared by liquid culture and purification; the recombination fusion protein can serve as the novel genetic engineering vaccine and can serve as a novel immunologic adjuvant for newcastle disease common vaccine. The chIL-2-HN fusion protein of the invention has favourable safety and no toxic or side effect, which is verified by experiments of animal immunoassay. In addition, the chIL-2-HN fusion protein can effectively strengthen the level of organism cellular immunity and humoral immunity and has wide application prospect.

The invention belongs to the technical field of biological pharmacy, and relates to an apolipoprotein modified bionic nano tumor vaccine as well as a preparation method and an application thereof. Based on the characteristics of dendritic cell (DC) phagocytic antigen, the bionic nano tumor vaccine is prepared, and the bionic nano tumor vaccine utilizes a macropinocytosis approach to increase the intake of DC to the vaccine, promote the maturation and antigen presentation of DC and improve the immune response effect in vivo. According to the nano vaccine, a biodegradable material is used as a nano core to encapsulate a hydrophobic immunologic adjuvant, lipid is used as a shell to load tumor-associated antigen peptides, and apolipoprotein is modified on the lipid, so that DC is efficiently activated to phagocytize the nano vaccine by utilizing a macropinocytosis pathway. The nanoformulation vaccine is suitable for preventing or treating tumors against one or more antigens or adjuvants.

The invention discloses a preparation method of a high-activity antigen-loaded dendritic cell. The method comprises the following steps of a, collecting and separating single karyocyte from peripheral blood; b, adding the single karyocyte obtained in the step a into DC (dendritic cell) serum-free medium, adding cytokines IL-4 and GM-CSF into the medium, putting in a 5 percent CO2 culture tank at 37 DEG C to culture, and collecting the dendritic cell after 6 days; and c, adding corresponding antigen and mycobacterium tuberculosis purified protein derivative (PPD) into the medium containing the dendritic cell collected in the step b, and keeping on culturing to obtain the high-activity antigen-loaded dendritic cell. According to the preparation method, PPD is added when tumor antigen is loaded to have an effect similar to immunologic adjuvant, so that the capability of DC in treating tumor antigen can be improved, and the killing activity of CTL (cytotoxic lymphocyte) generated by stimulation of the cells to tumor cells can be indirectly improved.

The invention provides Japanese encephalitis (JE) vaccine composition. The JE vaccine composition comprises a JE virus antigen of immunization effective quantity and water based vaccine adjuvant. The invention further provides a preparing method and application of the JE vaccine composition. The vaccine composition has good immunogenicity and immunizing protection. The immune effect of the JE vaccine composition is remarkably superior to that of single pig JE live vaccine and other live vaccine diluted by immunologic adjuvant. The clinical application prospects are good.

The invention relates to a self-combine compound nanometer cancer vaccine, and relative production. Wherein, said vaccine is formed by cancer cell membrane, protein molecule and DNA particle; the invention builds the cancer antigen molecule and immunologic adjuvant molecule on the eucaryon expression carrier, to anchor and express on the surface of cancer cell; then mixing the cells, to extract cell membrane, and decompose the cell membrane into the membrane liposome with anchored protein molecule, to be mixed with the DNA particles of cancer antigen molecule, immunity adjusting molecule, in certain buffer condition, to form the nanometer cancer vaccine. The invention can be used to treat several carcinomas, contagion, and non-contagion.

The invention provides horse anti-EBOV (Ebola virus) immune globulin F (ab')2 and a preparation method thereof. The preparation method comprises steps as follows: virus-like particles of a GP gene and a VP40 gene expressing EBOV-Z simultaneously are inactivated and purified and then are mixed with an immunologic adjuvant to be taken as immunogens, highly immunized plasma is obtained through repeated immunization of healthy horses, IgG protein is separated and purified, then the IgG protein is subjected to pepsase digestion, an enzyme-digested product is processed by a DEAE ion-exchange chromatographic column, an eluent is collected and subjected to desalination and freeze-drying, and the horse anti-EBOV immune globulin F (ab')2 is obtained. The horse anti-EBOV immune globulin F (ab')2 is an effective drug for preventing and treating Ebola hemorrhagic fever caused by EBOV and has remarkable curative effects for critical patients infected with the EBOV; the preparation method is controlled by adopting unique technological parameters and is suitable for industrial production, and the product is safe and reliable.

The invention provides application of S. pneumoniae protein to resisting infection of S. pneumoniae. The endopeptidase O (PepO) of S. pneumoniae is a subcutaneous immunologic adjuvant, and the prepared S. pneumoniae protein vaccines have the good protection effects on resisting infection of S. pneumoniae through mixing and fusing expression of the subcutaneous immunologic adjuvant and 673rd to 863rd amino acid peptide fragment of zinc metal protease B (ZmpB).